The moment the cannula infiltrated her daughter’s fragile skin, Dr. Nisha Narayanan’s reality fractured. In one sphere, she was a pediatric emergency medicine physician, a professional trained to anticipate, prevent, and mitigate medical crises. In the other, she was a mother, watching in helpless horror as her 11-month-old daughter, Leela, writhed in agony in a Scottish resuscitation bay.
The injury was not a mystery; it was a known, preventable complication of the medication being administered. Despite Dr. Narayanan’s gentle but firm warnings as a colleague, the clinical team adhered to a local protocol that prioritized older, cheaper drug formulations over safer, modern alternatives. What followed was not just a medical catastrophe for a toddler, but a profound confrontation with the systemic failures of accountability in international healthcare.
The Anatomy of an Error: A Chronology of Harm
The crisis began three weeks after the family’s relocation from New York City to Edinburgh. When Leela developed a prolonged febrile seizure—a common, usually benign occurrence in young children—her parents did what any parent would do: they sought help at a tertiary children’s hospital.
As the seizure persisted, the medical team moved to administer phenytoin, an anti-epileptic medication. Dr. Narayanan immediately recognized the danger. In the United States, fosphenytoin is the standard of care for pediatric status epilepticus. Unlike phenytoin, which is highly toxic to tissue if it leaks from an IV (extravasation), fosphenytoin is a prodrug that is significantly safer for delicate pediatric veins.
"I explained gently, then more firmly, that in the United States, fosphenytoin is preferred by nearly all pediatric emergency departments," Dr. Narayanan recalls. "I wasn’t trying to interfere; I wanted to trust the team caring for my daughter."
Her warnings were dismissed. The infusion proceeded. Three hours later, the team acknowledged that the cannula had infiltrated. The phenytoin had leaked into the surrounding tissue, causing a severe extravasation injury. The result was not merely a localized burn; it was a necrotic event that would eventually require emergency surgery, multiple skin grafts, three weeks of hospitalization, and the use of a vacuum-assisted closure (VAC) device to prevent systemic infection.
The Culture of Silence vs. The Culture of Inquiry
For Dr. Narayanan, the injury was only the beginning of a long, disillusioning process. As a physician who has spent her career in American academic medical centers, she expected the standard "second act" of a medical error: a formal acknowledgment, a transparent review, and a commitment to process improvement.
"I have always believed the measure of a health care system is not whether harm occurs, but how it responds when it does," she says. "Errors are inevitable, even in excellent hospitals. What matters is whether they become opportunities to learn or threats to manage."
However, the response from the Scottish institution was marked by a chilling silence. Requests for meetings were met with vague apologies, and formal complaints were treated as bureaucratic hurdles rather than opportunities for clinical reflection. A month after filing a detailed clinical critique supported by medical literature, the response was definitive: no error had occurred. Because the team had followed the "protocol" of using phenytoin, the injury was deemed an acceptable "complication" rather than a preventable failure.
Supporting Data: The Global Divide in Safety Standards
The disparity between the two systems Dr. Narayanan inhabits—the U.S. and the U.K.—is not merely one of resources, but one of philosophy. While American healthcare is often criticized for its inequitable access, its academic centers are frequently governed by a culture of "relentless scrutiny."
In the U.S., the fear of litigation, while often criticized for driving "defensive medicine," acts as a powerful catalyst for accountability. When a patient is harmed in a top-tier U.S. institution, the incident is frequently treated as "data." It is analyzed by morbidity and mortality (M&M) conferences, legal teams, and quality improvement committees. The goal is to ensure the error never happens again.
In contrast, the system Dr. Narayanan encountered abroad relied heavily on internal, opaque reviews. When protocols are treated as absolute, the individual clinician’s judgment is often stifled. If the "page" says the medication is acceptable, the injury becomes invisible. This, Dr. Narayanan argues, leads to a normalization of harm.
"When questioning is uncommon, early warnings are easy to overlook," she notes. During her daughter’s recovery, she encountered other children in wound care clinics suffering from similar extravasation injuries. These cases were handled in isolation, preventing the hospital from recognizing a potential systemic pattern that could be corrected with a simple change in the hospital’s formulary.
Institutional Responses and the Ombudsman’s Verdict
After escalating the issue to a national ombudsman, the resolution was equally disheartening. More than a year after the injury, the final word was that while the case had prompted "reflection," the conclusion remained that "protocol had been followed."
This creates a dangerous paradox: a system that functions perfectly on paper while failing the human being in front of it. By focusing solely on compliance with written guidelines, the institution stripped the clinical team of the ability to act on the specific, urgent warnings provided by a parent who happened to be a medical expert. The institutional logic became a shield against accountability rather than a framework for improvement.
Implications: The Future of Ethical Medical Practice
The implications of this case are significant for global health policy. We often look to universal, publicly funded healthcare systems as the gold standard for "humane" care. But Dr. Narayanan’s experience forces a difficult question: Does universal access guarantee universal safety?
"I believe deeply in universal health care," she writes. "But universal care also must mean universal safety and accountability, not merely universal access."
The danger of a system that refuses to acknowledge error is that it stagnates. If harm is not labeled as an error, there is no incentive to change the protocol. If the protocol is not changed, the next child receives the same treatment, faces the same risk, and suffers the same outcome.
For the medical community, the lesson is clear: transparency must be a reflex, not an aspiration. Systems that rely on internal, closed-door reviews are prone to the "normalization of deviance," where preventable harms are accepted as the cost of doing business.
Moving Toward a Culture of Learning
Leela is healing, though she bears the physical scars of her ordeal—a permanent reminder of a system that prioritized the protocol over the patient. She wears a brace, a small, tangible mark of an injury that, according to the hospital, never should have been categorized as a systemic failure.
Dr. Narayanan’s crusade is not for retribution. It is a plea for a shift in medical culture. She argues that we must move away from systems that view patients as problems to be managed and toward systems that view them as partners in safety.
"I want clinicians to feel safe questioning protocols," she says. "I want systems capable of saying: ‘This happened. It should not have. Here is what we are changing.’"
Ultimately, the article serves as a sobering reminder that the greatest danger in any medical system is not the potential for a mistake, but the institutional unwillingness to learn from it. Without the ability to admit fault, medicine ceases to be a science of improvement and becomes a rigid, defensive, and ultimately dangerous bureaucracy. True accountability in medicine, Dr. Narayanan concludes, is not found in the legal outcome of a complaint, but in the courage of an institution to look at its own failings and choose to do better.
